You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Treatment of the following infections when caused by CURAM 125/31.25 sensitive, beta-lactamase producing organisms: Skin and skin structure infections, including cases caused by beta-lactamase producing Staph. aureus, E. coli and Klebsiella sp. (only some strains may be sensitive). Urinary tract infections, including cases caused by beta-lactamase producing E. coli, P. mirabilis and Klebsiella sp. Upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing H. influenzae and M. catarrhalis, and otitis media, especially cases caused by beta-lactamase producing H. influenzae, M. catarrhalis and Staph. aureus. Lower respiratory tract infections, especially cases caused by beta-lactamase producing H. influenzae and M. catarrhalis. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to CURAM 125/31.25. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in Microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to CURAM 125/31.25 should not require the addition of another antibiotic due to the amoxycillin content of CURAM 125/31.25.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Treatment of the following infections when caused by CURAM 125/31.25 sensitive, beta-lactamase producing organisms: Skin and skin structure infections, including cases caused by beta-lactamase producing Staph. aureus, E. coli and Klebsiella sp. (only some strains may be sensitive). Urinary tract infections, including cases caused by beta-lactamase producing E. coli, P. mirabilis and Klebsiella sp. Upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing H. influenzae and M. catarrhalis, and otitis media, especially cases caused by beta-lactamase producing H. influenzae, M. catarrhalis and Staph. aureus. Lower respiratory tract infections, especially cases caused by beta-lactamase producing H. influenzae and M. catarrhalis. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to CURAM 125/31.25. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in Microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to CURAM 125/31.25 should not require the addition of another antibiotic due to the amoxycillin content of CURAM 125/31.25.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Treatment of the following infections when caused by CURAM 125/31.25 sensitive, beta-lactamase producing organisms: Skin and skin structure infections, including cases caused by beta-lactamase producing Staph. aureus, E. coli and Klebsiella sp. (only some strains may be sensitive). Urinary tract infections, including cases caused by beta-lactamase producing E. coli, P. mirabilis and Klebsiella sp. Upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing H. influenzae and M. catarrhalis, and otitis media, especially cases caused by beta-lactamase producing H. influenzae, M. catarrhalis and Staph. aureus. Lower respiratory tract infections, especially cases caused by beta-lactamase producing H. influenzae and M. catarrhalis. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to CURAM 125/31.25. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in Microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to CURAM 125/31.25 should not require the addition of another antibiotic due to the amoxycillin content of CURAM 125/31.25.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Treatment of the following infections when caused by CURAM 125/31.25 sensitive, beta-lactamase producing organisms: Skin and skin structure infections, including cases caused by beta-lactamase producing Staph. aureus, E. coli and Klebsiella sp. (only some strains may be sensitive). Urinary tract infections, including cases caused by beta-lactamase producing E. coli, P. mirabilis and Klebsiella sp. Upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing H. influenzae and M. catarrhalis, and otitis media, especially cases caused by beta-lactamase producing H. influenzae, M. catarrhalis and Staph. aureus. Lower respiratory tract infections, especially cases caused by beta-lactamase producing H. influenzae and M. catarrhalis. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to CURAM 125/31.25. However, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in Microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to CURAM 125/31.25 should not require the addition of another antibiotic due to the amoxycillin content of CURAM 125/31.25.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
